
Legal status of cannabis in the European Union (as of 25 September 2026)
- The EU has no single cannabis law: it sets a common framework for hemp farming, trade and drug trafficking, while recreational use is regulated by each Member State.
- CBD lawfully produced in one Member State may in principle be sold in another; a national ban is allowed only if it is suitable to protect public health and does not go beyond what is necessary. The Court held that such CBD is not a narcotic drug under the 1961 Single Convention (Articles 34 and 36 TFEU, Case C-663/18 Kanavape, paras 76 and 96).
- Industrial hemp qualifies for CAP direct payments only if the THC content of the variety does not exceed 0.3 % (Art. 4(4) Regulation (EU) 2021/2115); THC control methods are set by the Commission (Art. 60(4)(a) Regulation (EU) 2021/2116).
- Member States may restrict how hemp is grown, for example ban indoor hydroponic cultivation, if the restriction is suitable and proportionate for protecting public health (Case C-793/22 Biohemp Concept, 4 October 2024).
- Member States must make intentional unlawful cultivation of cannabis plants and drug trafficking a criminal offence (Art. 2(1)(b) Framework Decision 2004/757/JHA, as quoted in Case C-271/23).
- Rules on recreational cannabis differ widely: Germany allows adults to possess up to 25 g in public, 50 g at home and three plants (§ 3 and § 9 KCanG), while in Czechia personal use becomes a criminal offence only above 5 plants, 200 g at home or 50 g elsewhere, and plants with up to 1 % THC are excluded (§ 285 Czech Criminal Code).
“Články 34 a 36 SFEU musí být vykládány v tom smyslu, že brání vnitrostátní právní úpravě, která zakazuje uvádět na trh CBD, který je legálně vyprodukován v jiném členském státě, v případě, že je extrahován z celé rostliny cannabis sativa, a nikoli pouze z jejích vláken a semen, ledaže je tato právní úprava s to zaručit naplnění cíle ochrany veřejného zdraví a nepřekračuje meze toho, co je k dosažení tohoto cíle nezbytné.”
[Translation: “Articles 34 and 36 TFEU must be interpreted as precluding national legislation which prohibits the marketing of CBD lawfully produced in another Member State when it is extracted from the Cannabis sativa plant in its entirety and not solely from its fibre and seeds, unless that legislation is appropriate for securing the attainment of the objective of protecting public health and does not go beyond what is necessary for that purpose.”]
This overview is based on legislation and case law in the legal database Europaius. It is not legal advice.
- Polish cannabis supporters and especially patients who need cannabis are currently thanking former rapper and current politician Krzysztof Liroya-Marzec, nicknamed Liroy, for pushing legislation allowing the sale of medical cannabis in pharmacies
Just two years have passed since the former rapper Liroy entered political life in Poland and became a member of parliament. During that time, however, this significant figure in the Polish cannabis scene managed to push through a law that now allows Polish patients to legally obtain medical cannabis by prescription.
"After a long, exhausting battle, the first of November became the day Poland legalized cannabis for medical purposes."
Liroy was elected to parliament in 2015 as a member of the Kukiz' 15 party. He first proposed an amendment to the law regarding medical cannabis at the beginning of 2016.
The complete form of the proposal was quite drastically cut by parliament - for example, permission to grow cannabis for personal medical purposes was decisively rejected. Liroy immediately criticized the Ministry of Health's stance and made his opinion clear:
"Sick people are dying daily because of today's laws. I myself attend their funerals, talk to their families, and try to explain how we can change things for the better. You, lawmakers of our country, should go and try to tell the surviving family members what you say in the media."
After many negotiations and revisions, Liroy's proposal finally passed parliament and in the final vote won with a majority of 440 lawmakers voting in favor and only 2 against.

Medical Vs Recreational Use of Cannabis in Poland
The new law naturally does not completely legalize cannabis use. Medical cannabis is only permitted for patients who receive a prescription from their doctor and also an official permit from the regional pharmaceutical inspector.
Diseases, disabilities, and conditions that will allow patients to receive this permit include:
- Chronic pain
- Chemotherapy-induced nausea
- Multiple sclerosis
- Spasticity (Motor disorder, increased muscle tension)
- Resistant epilepsy
An interesting public survey from 2015 showed that 75% of Polish citizens believe that banning medical cannabis for patients suffering from the above disorders is immoral, cruel, and completely violates public citizens' rights.
Distribution of Medical Cannabis in Poland
Almost 90% of the 15,000 registered Polish pharmacies will be authorized to dispense medical cannabis by prescription, which should ultimately reach approximately 300,000 patients.
However, the question remains: will medical cannabis be available to patients at all?
The laws are green, but the production and import of medical cannabis is a problem of an entirely different caliber. Since Poland does not yet have a sufficiently sophisticated medical cannabis production system, it will need to be imported from countries like the Netherlands or Canada.
The estimated final price of medical cannabis will not be small: a gram of cannabis will cost patients around 350 crowns, which amounts to an excessive 11,000 crowns per month.
Author: Lisa Rough
Source: leafly.com



